HoPE (Hospice Preparation and Education)

Pilot Trial Evaluating Usability, Acceptability, and Feasibility of the HoPE (Hospice Preparation and Education) Web-Based Tool

The investigator will conduct a two-site, randomized, controlled study of the HoPE (Hospice Preparation and Education) web-based tool versus usual care to assess: Technology usability (primary), study feasibility (secondary), user acceptability (secondary), and hospice service conversion rate (exploratory). Technology usability will be assessed through a one-time quantitative survey using established instruments. Study feasibility and user accessibility will be assessed through trial enrollment and retention alongside analytics assessing tool usage (e.g. time spent on each page of the website). Conversion rate is the percent of patients introduced to hospice who eventually enroll. The investigators will evaluate in an exploratory manner the differential effect of HoPE versus usual care.

Study Overview

• Status: Withdrawn
• Conditions: Hospice Care
• Intervention / Treatment: Other: HoPE Website

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University Medical Center
    • Raleigh, North Carolina, United States, 27610
      • WakeMed Health & Hospitals

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 89 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Eligible for and referral made for home hospice services (Note: this excludes home palliative care, home infusion, home nursing, home physical therapy, and bridge services)
• Aged between 21 and 89
• Capacity to give consent
• Ability to speak and understand English

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Standard of Care
Experimental: Standard of Care + HoPE	Other: HoPE Website; Educational website focused on hospice care

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Technology usability as measured by System Usability Scale	To determine usability, the System Usability Scale will be administered to each participant in the intervention arm. As described by usability.gov: "The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking. Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average, however the best way to interpret your results involves "normalizing" the scores to produce a percentile ranking."	At study completion, up to 4 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study Feasibility as measured by enrollment efficiency	Enrollment efficiency will be measured by the percentage of patients approached who enroll in the study, with the goal of >50% enrollment.	At study completion, up to 4 months
Study Feasibility as measured by intervention completion	Intervention completion will be measured by the percentage of participants on the intervention arm who complete at least 50% of the modules within the intervention website, with a goal of >50% of the participants.	At study completion, up to 4 months
User Accessibility as measured by Net Promoter score	The Net Promoter scale is administered to participants in the intervention arm of the study only. This scale is an eleven-item likert scale assessing likelihood to recommend the intervention to a family member or friend. The percentage of participants who give a score of 0 through 6 is subtracted by the percentage of participants who give a score of 9 or 10 to give the overall Net Promoter score. This score is then compared to other scores of similar technologies.	At study completion, up to 4 months

Collaborators and Investigators

• Sponsor: Duke University
• Investigators: Principal Investigator: Arif Kamal, MD, Duke University

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2022
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): December 31, 2022

Study Registration Dates

• First Submitted: May 26, 2020
• First Submitted That Met QC Criteria: May 29, 2020
• First Posted (Actual): June 1, 2020

Study Record Updates

• Last Update Posted (Actual): March 18, 2022
• Last Update Submitted That Met QC Criteria: March 4, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: Pro00105058

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No